virginiamycin and Sinusitis

TWO MAIN GERMS: The risk of severe complications of acute bacterial sinusitis warrants empirical antibiotic therapy targeted against the two main causal agents: S. pneumoniae and H. influenzae.. A double-blind placebo-controlled randomized multicentric study conducted with two treatment arms including 310 patients has demonstrated that pristinamycin, 2 g/d for 8 days, has a clinical efficacy equivalent to cefuroxime axetil, 500 mg/d.. Pristinamycin is an interesting alternative to beta-lactams for the first intention treatment of purulent acute sinusitis in adults. Its efficacy against penicillin-resistant pneumococci and H. influenzae is a further reason for its use in case of failure after conventional treatments.

Topics: Acute Disease; Adult; Age Factors; Ambulatory Care; Female; Humans; Male; Placebos; Sinusitis; Treatment Outcome; Virginiamycin

TREATMENT OF SINUSITIS: For both acute rhinosinusitis in patients with no past history where S. pneumoniae and H. influenzae are the main causal agents, or recurrent sinusitis in a chronic background where anaerobic bacteria are increasingly implicated, pristinamycin is one of the rare compounds which can be expected to be effective and is a treatment of choice for an empirical strategy. LOWER RESPIRATORY TRACT INFECTIONS: Besides high-risk subjects with non-microbiologically proven bronchial infection, where enterobacteriaceae could involve a pristinamycin is a useful alternative to the conventional strategy (i.e.: amoxicillin, macrolides and cotrimoxazole) in the treatment of LRT infection.

Topics: Acute Disease; Adult; Amoxicillin; Bronchial Diseases; Bronchitis; Female; Humans; Macrolides; Male; Respiratory Tract Infections; Rhinitis; Sinusitis; Trimethoprim, Sulfamethoxazole Drug Combination; Virginiamycin